|1.||Pucci, E: 2 articles (01/2002 - 01/2001)|
|2.||Uitdehaag, B: 2 articles (01/2002 - 01/2001)|
|3.||Taus, C: 2 articles (01/2002 - 01/2001)|
|4.||Solari, A: 2 articles (01/2002 - 01/2001)|
|5.||Giuliani, G: 2 articles (01/2002 - 01/2001)|
|6.||Desnuelle, Claude: 1 article (12/2015)|
|7.||Mantegazza, Renato: 1 article (12/2015)|
|8.||Verdino, Ralph J: 1 article (12/2015)|
|9.||Zamani, Payman: 1 article (12/2015)|
|10.||Meisel, Andreas: 1 article (12/2015)|
|1.||Septic Shock (Toxic Shock Syndrome)
|2.||Alzheimer Disease (Alzheimer's Disease)
01/01/1991 - "The two clinical studies in the literature are contradictory, so potassium channel blockers may still merit trial in Alzheimer disease."
04/01/1992 - "This review of the literature examines systematically the data currently available for potassium-channel blockers to reassess their clinical potential in Alzheimer disease. "
01/01/1991 - "Potassium channel blockers: could they work in Alzheimer disease?"
04/01/1992 - "The conclusion is that potassium-channel blockers may have been dismissed prematurely for the treatment of Alzheimer disease, an impression supported by data indicating intimate relationships between potassium-channel blockade and cholinergic transmission."
04/01/1992 - "A group of potassium-channel blockers-acetylcholine releasers: new potentials for Alzheimer disease? "
07/01/2006 - "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment."
10/01/1992 - "Potassium channel blockers from Ruta--a new approach for the treatment of multiple sclerosis."
01/01/2002 - "The potassium channel blockers 4-aminopyridine (AP) and 3,4-diaminopyridine (DAP) increase nerve conduction in demyelinated nerve fibers, and have been proposed as a symptomatic therapy for people with multiple sclerosis (MS). "
01/01/2001 - "Because of their ability to increase nerve conduction in demyelinated nerve fibers, potassium channel blockers 4-aminopyridine (AP) and 3,4-diaminopyridine (DAP) have been proposed as a symptomatic therapy for people with multiple sclerosis (MS). "
08/01/1994 - "Only 5-methoxypsoralen is a largely selective blocker of predominantly the axolemmal potassium channels, which is the characteristic required by our previously proposed working hypothesis for the mechanism of potassium-channel blockers in demyelinating diseases, in particular multiple sclerosis. "
|4.||Spinal Cord Injuries (Spinal Cord Injury)
10/14/1996 - "Changes in pharmacological sensitivity of the spinal cord to potassium channel blockers following acute spinal cord injury."
01/01/2007 - "These include the Surgical Treatment for Acute Spinal Cord Injury Study (STASCIS) Trial to evaluate the role and timing of surgical decompression for acute SCI, neuroprotection with the semisynthetic second generation tetracycline derivative, minocycline; aiding axonal conduction with the potassium channel blockers, neuroregenerative/neuroprotective approaches with the Rho antagonist, Cethrin; the use of anti-NOGO monoclonal antibodies to augment plasticity and regeneration; as well as cell-mediated repair with stem cells, bone marrow stromal cells, and olfactory ensheathing cells. "
|5.||Nervous System Diseases (Neurological Disorders)
12/01/2014 - "Aminopyridines are potassium channel blockers that increase the excitability of nerve cells and axons; therefore, they are widely used to treat different neurological disorders. "
09/30/2011 - "4-Aminopyridine (4-AP) and tetraethylammonium (TEA) are wide-spectrum potassium channel blockers which based on the animal model studies and clinical trials have beneficial effects in treatment of several neurological disorders such as ataxia, Alzheimer disease and multiple sclerosis. "
|1.||Adenosine Triphosphate (ATP)
|2.||4-Aminopyridine (4 Aminopyridine)
|3.||Tetraethylammonium (Tetraethylammonium Bromide)